

***Amendments to the Claims:***

This listing of claims will replace all prior versions of claims.

1.- 17. (Cancelled)

18. (Currently Amended) An isolated polypeptide encoded by the polynucleotide sequence consisting of SEQ ID NO:1 ~~claim 1~~.

19. (Cancelled)

20. (Currently Amended) The isolated polypeptide according to claim 18 ~~19~~, which is encoded by a nucleotide sequence set forth in SEQ ID NO:1, wherein the polynucleotide comprises a peptide having an activity selected from the group consisting of vascular endothelial cell growth activity, activity in promoting transcription from c-fos promoter, activity in promoting transcription from VEGF promoter, and angiogenesis activity.

21. (Currently Amended) The isolated polypeptide according to claim 39 ~~19~~, which has an amino acid sequence set forth in SEQ ID NO:2, wherein the polypeptide comprises an activity selected from the group consisting of vascular endothelial cell growth activity, activity in promoting transcription from c-fos promoter, activity in promoting transcription from VEGF promoter, and angiogenesis activity.

22. (Currently Amended) The isolated polypeptide according to claim 21 ~~19~~, which has angiogenesis activity.

23. (Currently Amended) The isolated polypeptide according to claim 21 ~~19~~, which has vascular endothelial cell growth activity.

24. (Currently Amended) A pharmaceutical composition for angiogenesis, which comprises the polypeptide of claim 21 ~~19~~.

25. (Currently Amended) A pharmaceutical composition for growth of vascular endothelial cells, which comprises the polypeptide of claim 18 19.

26. (Currently Amended) A pharmaceutical composition for the treatment of a disease selected from the group consisting of occlusive arterial disease, arteriosclerosis obliterans, Buerger disease, angina, myocardial infarction, cerebral infarction, ischemic heart disease, and ischemic cerebral disease, which comprises the polypeptide of claim 18 19.

27.-38. (Cancelled)

39. (New) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

40. (New) A pharmaceutical composition for growth of vascular endothelial cells, which comprises the polypeptide of claim 39.

41. (New) A pharmaceutical composition for the treatment of a disease selected from the group consisting of occlusive arterial disease, arteriosclerosis obliterans, Buerger disease, angina, myocardial infarction, cerebral infarction, ischemic heart disease, and ischemic cerebral disease, which comprises the polypeptide of claim 39.

42. (New) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2 or a fragment thereof, wherein said fragment comprises an activity selected from the group consisting of vascular endothelial cell growth activity, activity in promoting transcription from c-fos promoter, activity in promoting transcription from VEGF promoter, and angiogenesis activity.

43. (New) The isolated polypeptide of claim 42, wherein the activity is vascular endothelial cell growth activity.

44. (New) The isolated polypeptide of claim 42, wherein the activity is in promoting transcription from c-fos promoter.

45. (New) The isolated polypeptide of claim 42, wherein the activity is in promoting transcription from VEGF promoter.

46. (New) The isolated polypeptide of claim 42, wherein the activity is in angiogenesis activity.